Esperion Therapeutics News

Esperion Receives Five Year Patent Extension For Bempedoic Acid

Esperion Receives Five Year Patent Extension For Bempedoic Acid

BenzingaMay 14 20:16

Esperion Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Esperion Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow JonesMay 8 21:43

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $16 price target.

BenzingaMay 8 21:33

Esperion Therapeutics Inc (ESPR) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues ...

Yahoo FinanceMay 8 15:04

Needham: Reiterated the Esperion Therapeutics (ESPR.US) rating, adjusted from buy to buy rating, target price $8.00.

Needham: Reiterated the Esperion Therapeutics (ESPR.US) rating, adjusted from buy to buy rating, target price $8.00.

Zhitong FinanceMay 8 02:01

Needham Reiterates Buy on Esperion Therapeutics, Maintains $8 Price Target

Needham analyst Serge Belanger reiterates Esperion Therapeutics with a Buy and maintains $8 price target.

Analyst UpgradesMay 8 01:57

Earnings Call Summary | Esperion Therapeutics(ESPR.US) Q1 2024 Earnings Conference

The following is a summary of the Esperion Therapeutics, Inc. (ESPR) Q1 2024 Earnings Call Transcript:Financial Performance:Esperion Therapeutics reported a record Q1 2024 revenue of $137.7 million, t

Futu NewsMay 7 23:06 · Conference Call

Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars

Tuesday, Esperion Therapeutics (NASDAQ:ESPR) reported first-quarter revenues of $137.74 million, up 467% Y/Y, surpassing the consensus of $84.51 million.The company reported an EPS of $0.34, a turnaro

BenzingaMay 7 22:20

Esperion Therapeutics, Inc. (ESPR) Q1 2024 Earnings Call Transcript

Esperion Therapeutics, Inc. (ESPR) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 7 22:05

Investor Sentiment Muted After Rate Cut Optimism, Stifling US Equity Futures Pre-Bell

US equity futures were flat ahead of Tuesday's opening bell as traders took a breather following gains fueled by hopes of rate cuts from the Federal Reserve. Dow Jones Industrial Average futures gaine

MT NewswiresMay 7 20:56

Esperion Therapeutics Inc (ESPR) Surpasses Q1 Revenue Forecasts With a 467% Increase

Yahoo FinanceMay 7 20:55

Esperion Therapeutics | 10-Q: Quarterly report

Futu NewsMay 7 20:54 · Announcements

Top Premarket Gainers

Esperion Therapeutics (ESPR) shares surged more than 25% Tuesday premarket after the company posted improved Q1 financial results. FibroGen (FGEN) shares rose nearly 20% after the company reported a n

MT NewswiresMay 7 19:36

Esperion Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Issued FY24 Revenue Guidance.

Esperion Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Issued FY24 Revenue Guidance.

BenzingaMay 7 19:24

Esperion Therapeutics (ESPR.US): The 2024 Q1 financial report achieved revenue of US$137.7 million, previous value of US$24.59 million, expected value of US$84.51 million; earnings per share were US$0.34, previous value of -0.79 USD, and expected value of

Esperion Therapeutics (ESPR.US): The 2024 Q1 financial report achieved revenue of US$137.7 million, previous value of US$24.59 million, expected value of US$84.51 million; earnings per share were US$0.34, previous value of -0.79 USD, and expected value of US$0.05.

Zhitong FinanceMay 7 18:20

Esperion Therapeutics Sees FY24 Revenues $225M-$245M, Including $20M In Non-cash Expenses Related To Stock Compensation

Esperion Therapeutics Sees FY24 Revenues $225M-$245M, Including $20M In Non-cash Expenses Related To Stock Compensation

BenzingaMay 7 18:04

Earnings Flash (ESPR) ESPERION THERAPEUTICS Posts Q1 EPS $0.34, Vs. Street Est of $-0.01

06:03 AM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (ESPR) ESPERION THERAPEUTICS Posts Q1 EPS $0.34, vs. Street Est of $-0.01

MT NewswiresMay 7 18:03

Esperion Therapeutics Q1 EPS $0.34 Beats $0.05 Estimate, Sales $137.74M Beat $84.51M Estimate

Esperion Therapeutics (NASDAQ:ESPR) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.05 by 580 percent.

BenzingaMay 7 18:02

Esperion Therapeutics 1Q EPS 34c >ESPR

Esperion Therapeutics 1Q EPS 34c >ESPR

Dow JonesMay 7 18:00

Press Release: Esperion Reports First Quarter 2024 Financial Results

Esperion Reports First Quarter 2024 Financial Results -- Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally -- -- Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 M

Dow JonesMay 7 18:00